Tourmaline Bio Names Ryan Robinson As CFO, Effective June 25
$TRML
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Tourmaline Bio Names Ryan Robinson As CFO, Effective June 25
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2023 | $41.00 | Buy | Jefferies |
| 12/4/2023 | $48.00 | Buy | H.C. Wainwright |
| 11/17/2023 | $43.00 | Buy | Truist |
| 10/31/2023 | $50.00 | Buy | Guggenheim |
| 10/25/2023 | $65.00 | Overweight | Piper Sandler |
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19th Annual Cardiometabolic Health Congress in October 2024 – – Cash, cash equivalents and investments of $314.4 million as of September 30, 2024, providing cash runway into 2027 – NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a lat
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conferences: Truist Securities BioPharma Symposium, New YorkPanel: Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle IllnessesThursday, November 7, 2024 at 2:35 pm ET Guggenheim Securities Healthcare Innovation Conference, BostonFireside ChatTuesday, November 1
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a webinar, Understanding the Genetic Validation for IL-6 Inhibition in Cardiovascular Disease, featuring Dr. Dipender Gill, CEO and Founder of Sequoia Genetics. The webinar will be held on Friday, November 1, at 9:30 AM ET and will explore the latest advancements in leveraging human genetics to inform therapeutic strategies targeting IL-6 signaling pathways. Dr. Gill, a leader in leveragi
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. "I am honored to announce these additions to our Board of Directors and welcome their operationa
NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as Chairman of the Board. "We are absolutely thrilled that Clay has joined Tourmaline as Chairman of the Board," said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. "Clay built Seagen into one of the largest independent biotech companies in the world by taking a therapeutic concept and developing from it multiple successful medicines
S-3 - Tourmaline Bio, Inc. (0001827506) (Filer)
10-Q - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
Jefferies initiated coverage of Tourmaline with a rating of Buy and set a new price target of $41.00
H.C. Wainwright resumed coverage of Tourmaline with a rating of Buy and set a new price target of $48.00
Truist initiated coverage of Tourmaline with a rating of Buy and set a new price target of $43.00
HC Wainwright & Co. analyst Yi Chen reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $48 price target.